Stay informed with the latest litigation news. Explore now

Anticancer Drug Containing Alpha, Alpha, Alphatrifluorothymidine And Thymidine Phosphorylase Inhibitor - EP1849470B2

EP1849470

TAIHO PHARMACEUTICAL
Application Number
EP06712292A
Filing Date
Jan 25, 2006
Status
Patent Maintained As Amended
Feb 16, 2024
Grant Date
Mar 20, 2024
External Links
Slate, Register, Google Patents
Similar Patents facing opposition

Bibliography

The patent EP1849470B2 was granted to Taiho Pharmaceutical on Mar 20, 2024 following the initial filing on Jan 25, 2006 under the application number EP06712292A . The current legal status of the patent is Patent Maintained As Amended.

Patent Summary

Patent Family New

Patent Family

Patent Oppositions (2)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateOpposition Status

Get instant alerts for new oppositions and patent status changes

GENERICS UKMar 21, 2018 -
STADA ARZNEIMITTELMar 21, 2018 -

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history, including filings, correspondence, and decisions made by patent offices. These documents are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination. It also includes the oppositions documents filed against the patent.

  • Date

    Description

  • Get instant alerts for new documents